文献速递抗栓抗凝管理药物相互作用药物不良反应与药物警戒

直接口服抗凝药联合氯吡格雷的大出血风险:回顾性队列研究

Risk of Major Bleeding Associated with Concomitant Direct-Acting Oral Anticoagulant and Clopidogrel Use: A Retrospective Cohort Study.
PubMed 文献 · Drug Saf · 2023-12-23

本研究基于美国商业保险数据库的回顾性队列,比较利伐沙班+氯吡格雷与阿哌沙班+氯吡格雷联合治疗的大出血风险。结果显示两组大出血风险相似(IPTW HR 1.13,95%CI 0.78-1.63),且既往单药治疗类型不影响该风险。

要点

  • 利伐沙班+氯吡格雷与阿哌沙班+氯吡格雷的大出血风险相似。
  • 联合治疗前使用DOAC或氯吡格雷单药不影响大出血风险。
  • 临床选择DOAC联合氯吡格雷时,大出血风险并非关键区分因素。

核心结论

  • 利伐沙班+氯吡格雷与阿哌沙班+氯吡格雷联合治疗的大出血风险相似。

研究设计与样本

  • 回顾性队列研究,使用Merative™ Marketscan Research Databases纳入2015-2018年美国商业保险成人。
  • 队列包括2895名利伐沙班+氯吡格雷用户和3628名阿哌沙班+氯吡格雷用户,采用IPTW平衡组间。
  • 中位随访时间为61天(范围73天)。

主要发现

  • 利伐沙班+氯吡格雷组与阿哌沙班+氯吡格雷组的大出血发生率分别为7.96和7.38每100人年(IPTW)。
  • IPTW风险比(HR)为1.13(95%CI 0.78-1.63),两组风险无显著差异。
  • 在联合治疗前接受DOAC或氯吡格雷单药治疗的亚组中,利伐沙班+氯吡格雷组IPTW HR为0.66(95%CI 0.33-1.32)。
  • 阿哌沙班+氯吡格雷组IPTW HR为1.10(95%CI 0.55-2.23),单药类型不影响大出血风险。

临床怎么用

  • 对于需要DOAC联合氯吡格雷的患者,利伐沙班和阿哌沙班的大出血风险相似,选择时可综合考虑其他因素。
  • 联合治疗前使用DOAC或氯吡格雷单药不影响后续大出血风险,无需据此调整选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIM: Combined anticoagulant-antiplatelet therapy is often indicated in adults with cardiovascular disease and atrial fibrillation or venous thromboembolism. The study aim was to assess the comparative risk of bleeding between rivaroxaban and apixaban when combined with clopidogrel. METHODS: We conducted a retrospective cohort study of commercially insured US adults newly treated with a combination of rivaroxaban+clopidogrel or apixaban+clopidogrel (2015-2018) using Merative™ Marketscan Research Databases. We used propensity score-based inverse probability of treatment weighting (IPTW) to balance the treatment groups. Weighted Cox proportional hazards regression was used to estimate the risk of major bleeding. RESULTS: The study cohort included 2895 rivaroxaban+clopidogrel users and 3628 apixaban+clopidogrel users. The median (range) duration of follow up was 61 (73) days. Rivaroxaban+clopidogrel users had a similar risk of major bleeding compared with apixaban+clopidogrel users (IPTW incidence rate per 100 person-years 7.96 vs 7.38; IPTW hazard ratio [HR] 1.13 [95% CI 0.78-1.63]). In the subcohort of adults who were treated with DOAC or clopidogrel monotherapy prior to the combined therapy, the risk of major bleeding did not differ by the drug of monotherapy (IPTW HR for rivaroxaban+clopidogrel group: 0.66 [95% CI 0.33-1.32]; IPTW HR for apixaban+clopidogrel group: 1.10 [95% CI 0.55-2.23]) CONCLUSIONS: In our study of commercially insured US adults, the concomitant use of rivaroxaban+clopidogrel and apixaban+clopidogrel conferred a similar risk of major bleeding. DOAC versus clopidogrel monotherapy prior to the concomitant therapy did not influence the risk of major bleeding.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Hwang YJ, Chang HY, Metkus T, et al. Risk of Major Bleeding Associated with Concomitant Direct-Acting Oral Anticoagulant and Clopidogrel Use: A Retrospective Cohort Study. Drug Saf. 2023. PMID: 38141156. doi:10.1007/s40264-023-01388-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。